Picture of Eli Lilly and logo

LLY — Eli Lilly and News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion (updated)

UPDATE 3-Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion

Adds Lilly's response in paragraph 5

- Drugmaker Eli Lilly LLY.N has signed an oncology research collaboration and licensing agreement worth up to $5.9 billion with Stipple Bio, the privately held biotech firm said on Monday.

The deal gives Lilly access to Stipple Bio's technology, which is designed to identify molecules that can distinguish cancer cells from healthy tissue, potentially enabling Lilly to develop therapies that are more effective and cause fewer side effects.

Stipple Bio will receive an upfront payment, an equity investment from Lilly and aggregate payments up to $5.9 billion in research, development and commercial milestone payments, as well as tiered royalties on product sales if any therapies resulting from the collaboration reach the market, the biotech firm said.

The companies did not disclose the size of the upfront payment or Lilly's equity investment.

Lilly declined to comment beyond the company's announcement of the deal.

The partnership adds to Lilly's efforts to expand its oncology pipeline as the drugmaker seeks to grow beyond its blockbuster diabetes and obesity medicines.

Lilly's oncology portfolio includes breast cancer drug Verzenio and blood cancer drug Jaypirca. The company is also developing a range of experimental cancer treatments, including targeted therapies, antibody-drug conjugates and immuno-oncology medicines.

Stipple Bio, based in Cambridge, Massachusetts, is developing its own pipeline of precision oncology therapies. Its lead candidate, antibody-drug conjugate STP-100, is expected to enter an early-stage trial in early 2027 in solid tumors, including pancreatic cancer.


(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)

((siddhi.mahatole@thomsonreuters.com;))

Recent news on Eli Lilly and

See all news